Citalopram (marketed as Celexa) Information
Citalopram (marketed as Celexa) Information
Suppression of JNK Pathway Drives Resistance to Endocrine and CDK4/6 Therapy in ER-Positive Breast Cancer
Researchers have identified suppression of the JNK pathway, particularly loss of MAP2K7, as a key driver of resistance to endocrine…
How League is Driving Towards a N of 1 in Healthcare
In healthcare, “personalized” often still means grouping people into broad categories — diabetics, 50-something women, post-op knee patients. League’s goal…
RestorixHealth Announces 2025 Center Recognition Awards
METAIRIE, La.–(BUSINESS WIRE)– #WhereHealingHappens–RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce the wound and hyperbaric center…
Lumaegis Secures $200,000 in Pre-Seed Funding to Accelerate FDA De Novo Certification—Propelling Its Breakthrough Sterilization Technology Toward Market Readiness
AUSTIN, Texas–(BUSINESS WIRE)–Lumaegis accelerating the path to market for its pioneering sterilization technology.
LY01011, Biosimilar of Denosumab, Meets Primary End Point in Study
When treating patients with bone metastases, the biosimilar demonstrated equivalent safety and efficacy to its reference product.
Six Data Transfer Insights for Tech Teams: How Legacy Data Boosts Efficiency in Cardiac Care
The following is a guest article by Christy Bricker, CPHIMS, Vice President Strategic Services at MURJ Effective management of patients…
Stop & Shop to close 7 e-commerce warerooms
The grocer expects to offer “an even better omnichannel customer experience” after shuttering the facilities, according to a spokesperson.
ModivCare files for bankruptcy with over $1.4B in debt
The medical transportation firm blamed mounting headwinds for its financial challenges, including labor cost inflation and declining reimbursements from public…
UPS preps added fee for US imports starting Sept. 8
The $2.50 international processing fee, which applies to three services, comes as parcel carriers grapple with the looming end of…